Ar­ray wres­tles FDA OK for its MEK/BRAF melanoma com­bo, to hit the phar­ma­cy as Mek­tovi and Braftovi

Watch out No­var­tis.

Just a few weeks af­ter turn­ing up at AS­CO with pos­i­tive da­ta to show off, Ar­ray Bio­Phar­ma $AR­RY has nailed an FDA ap­proval for its MEK in­hibitor binime­tinib, which will be sold as Mek­tovi, as well as en­co­rafenib — a BRAF in­hibitor now dubbed Braftovi.

This is the first OK for its com­bo, which is slat­ed to go up pri­mar­i­ly against No­var­tis’ ri­val duo Tafin­lar+Mekin­ist in the ad­vanced BRAF mu­tant melanoma sec­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER